Forward Dynamics: Modern Insights into Mitral Systolic Anterior Motion
Authors:
- Fatima Zahra Samet BouhaikFBFatima Zahra Samet Bouhaik
- Ilenia MonacoIMIlenia Monaco
- Mounia SedratiMSMounia Sedrati
- Alix BouvetABAlix Bouvet
- Benedicte GervaisBGBenedicte Gervais
- Valeria TrivelloniVTValeria Trivelloni
- Yassine BencharefYBYassine Bencharef
- Fouad Mohammed SekkalFSFouad Mohammed Sekkal
- Dario BottiglieroDario Bottigliero
Open Access
- 19 August 2026
- journal article
- review article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (8) , 397
Abstract
Systolic anterior motion (SAM) of the mitral valve can occur either in association with or in the absence of hypertrophic obstructive cardiomyopathy (HOCM). SAM induces dynamic left ventricular outflow tract obstruction (LVOTO) and, in the majority of cases, is associated with a substantial degree of mitral regurgitation (MR) that significantly impacts patient morbidity and mortality. This narrative review explores the contemporary understanding of the pathophysiology, diagnosis, and management of SAM, focusing particularly on surgical strategies and the novel therapeutic class of cardiac myosin inhibitors. Extended septal myectomy remains the gold-standard treatment for HOCM-related SAM, yielding superior long-term outcomes compared to alcohol septal ablation (ASA). Advanced imaging modalities, including three-dimensional transesophageal echocardiography (3D-TEE), enable precise pre-operative characterization of the mitral valve apparatus. Some patients may benefit from septal reduction strategies while concomitant mitral valve interventions are generally reserved for highly selected cases with intrinsic valve pathology or persistent residual SAM, thereby avoiding unnecessary valvular manipulation and its potential hemodynamic risks. Mavacamten, a selective cardiac myosin inhibitor, represents an important advance in pharmacological management, achieving a mean LVOT gradient reduction of 37.2 mmHg in symptomatic patients. Furthermore, data from the MARVEL registry confirm the real-world clinical efficacy of mavacamten in obstructive hypertrophic cardiomyopathy, with 86% of patients successfully down-staged to NYHA functional class I–II. Although ASA serves as a viable alternative to surgery, it entails a higher risk of conduction abnormalities requiring permanent pacemaker implantation and subsequent re-intervention. Beyond classical hypertrophic SAM, this review addresses the diagnosis and management of post-mitral repair complications and non-hypertrophic variants. Optimal management and risk stratification remain an evolving field requiring a multidisciplinary Heart Team approach, leverage of advanced imaging, and adoption of novel medical therapies. Interventional strategies must be carefully tailored to maximize the efficacy-to-safety profile on an individualized patient basis.Keywords
This publication has 107 references indexed in Scilit:
- Outcomes and Sex Differences in Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy–Insights from a Japanese Nationwide RegistryThe American Journal of Cardiology, 2026
- Changes in CMR-derived ventricular strain, fibrosis progression and outcomes in hypertrophic cardiomyopathyThe International Journal of Cardiovascular Imaging, 2026
- Left Ventricular Outflow Tract Modification During Robotic Mitral Valve RepairThe Annals of Thoracic Surgery, 2025
- Repeated Systolic Anterior Motion of the Mitral Valve After Double Outlet Right Ventricle RepairAnnals of Thoracic Surgery Short Reports, 2024
- Treatment Strategies for Hypertrophic Cardiomyopathy: Alcohol Septal Ablation and Procedural Step-by-Step TechniqueThe American Journal of Cardiology, 2024
- Single Center Experience of Percutaneous Septal Ablation in Patients With Hypertrophic Cardiomyopathy With A Novel Agent: PolidocanolThe American Journal of Cardiology, 2022
- Pulmonary congestion during Exercise stress Echocardiography in Hypertrophic CardiomyopathyThe International Journal of Cardiovascular Imaging, 2022
- Comparison of Surgical Ventricular Septal Reduction to Alcohol Septal Ablation Therapy in Patients with Hypertrophic CardiomyopathyThe American Journal of Cardiology, 2022
- Papillary Muscle Reorientation for Systolic Anterior Motion After Mitral Valve RepairThe Annals of Thoracic Surgery, 2021
- A Tale of Two Pressures- Medical Management Dilemmas in Post-TAVR LVOT ObstructionJournal of Cardiac Failure, 2019